G01N2400/00

FLOW DEVICE

The present invention relates to methods for the detection of an analyte, such as coronavirus (e.g. SARS-CoV-2) or other virus particles and proteins, in a test sample. The invention also provides a flow device for use in such methods. Additionally, there is provided a coronavirus-binding reagent having the structure [sialic acid]-[linker]-[polymer]-[gold nanoparticle] for use in the devices and methods of the invention.

IMMUNOASSAY AND MEASUREMENT REAGENT FOR LEUCINE-RICH ALPHA2 GLYCOPROTEIN

An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.

Subtilase cytotoxin B subunit mutant

A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having α2-3-linked N-glycolylneuraminic acid and glycans having α2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having α2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having α2-3-linked N-glycolylneuraminic acid.

PATHOGEN BINDING METHODS AND COMPOSITIONS

Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. The microbe-targeting or microbe-binding molecules can comprise a microbe surface-binding domain linked to a portion of an Fc region. Further, the microbe-targeting molecules can be conjugated to substrate (e.g., a magnetic particle) to form a microbe-targeting substrate. Such microbe-targeting molecules and/or substrates and the kits comprising the same can be used in various applications, such as diagnosis and/or treatment of an infection caused by microbes. Moreover, the microbe-targeting molecules and/or substrates can be easily regenerated after use.

METHOD OF MAKING NANOPARTICLE COLLOID AND NANOPOROUS LAYER
20220183599 · 2022-06-16 ·

This disclosure relates to a glucose-sensing electrode including a nanoporous metal layer and an electrolyte ion-blocking layer formed over the nanoporous metal layer. The nanoporous metal layer is capable of oxidizing both glucose and maltose without an enzyme specific to glucose in the glucose-sensing electrode. The electrolyte ion-blocking layer is configured to inhibit Na.sup.+, K.sup.+, Ca.sup.2+, Cl.sup.−, PO.sub.4.sup.3− and CO.sub.3.sup.2− from diffusing toward the nanoporous metal layer such that there is a substantial discontinuity of a combined concentration of Na.sup.+, K.sup.+, Ca.sup.2+, Cl.sup.−, PO.sub.4.sup.3− and CO.sub.3.sup.2− between over and below the electrolyte ion-blocking layer.

Platelet biomarkers and diagnostic methods for vascular diseases
11360097 · 2022-06-14 ·

The present invention relates to biomarkers and diagnostic and prognostic methods for vascular diseases. In particular, proteins of platelet-derived exosomes have been identified as biomarkers that can be used to detect platelet activation associated with pathogenesis of vascular diseases, including cardiovascular and cerebrovascular diseases. The invention also provides compositions for detecting biomarkers as well as compositions and methods useful for treating vascular diseases.

ANALYSIS METHOD, MICROORGANISM IDENTIFICATION METHOD, AND TESTING METHOD
20220178941 · 2022-06-09 · ·

An analysis method incudes: preparing a sample containing microorganisms; placing the microorganisms under a first condition and then performing a first mass spectrometry on a substance produced by the microorganisms; and obtaining information on characteristics or classifications of the microorganisms contained in the sample on a basis of a difference between a first data obtained in the first mass spectrometry and a second data obtained when a second mass spectrometry is performed on a substance produced by the microorganisms after having been placed under a second condition as well as a reference data in which classifications or characteristics of the microorganisms are associated with the data obtained in the mass spectrometry of the microorganisms, in which the first condition and the second condition differ in a sugar concentration or an oxygen concentration in an environment in which the microorganisms are placed.

Methods of enhancing MS detection of tagged glycans

Methods for derivatization of biomolecules including glycans or other biopolymers with one or more fluorescent, MS active compounds by reductive amination or rapid tagging in order to produce derivatized glycan having a pKa>7 and between about 200 Å.sup.2 and about 1000 Å.sup.2 of nonpolar surface area are described.

Rapid fluorescence tagging of glycans and other biomolecules with enhanced MS signals

Reagents comprising MS active, fluorescent molecules with an activated functionality for reaction with amines useful in tagging biomolecules such as N-glycans and uses thereof are taught and described. In particular embodiments, the MS active, fluorescent molecules are of the compound of the Formula III ##STR00001##
or of the Formula IV ##STR00002##
where R.sup.1, R.sup.2 and R.sup.3 are defined herein.

IMMUNOCHROMATOGRAPHIC KIT AND METHOD FOR DETECTING MYCOBACTERIUM TUBERCULOSIS

An object of the present invention is to provide an immunochromatographic kit and a method, which are capable of detecting Mycobacterium tuberculosis with high-sensitivity and specificity. According to the present invention, an immunochromatographic kit for detecting Mycobacterium tuberculosis is provided, the kit including: a label substance modified with a first antibody against lipoarabinomannan; a porous carrier having a reaction site holding a second antibody against lipoarabinomannan; a compound containing silver; and a reducing agent reducing silver ions, in which at least one of the first antibody or the second antibody is a monoclonal antibody.